Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Pamiparib |
Synonyms | |
Therapy Description |
Pamiparib (BGB-290) inhibits PARP1 and PARP2, potentially resulting in increased sensitivity to DNA damaging agents (AACR; 2015. Abstract nr 1651, PMID: 32652442). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Pamiparib | BGB-290|BGB290 | PARP Inhibitor (Pan) 31 | Pamiparib (BGB-290) inhibits PARP1 and PARP2, potentially resulting in increased sensitivity to DNA damaging agents (AACR; 2015. Abstract nr 1651, PMID: 32652442). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
IDH1 R132C | cholangiocarcinoma | no benefit | Pamiparib | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, cholangiocarcinoma patient-derived xenograft (PDX) cell lines harboring IDH1 R132C were insensitive to Pamiparib (BGB-290) in culture and did not inhibit tumor growth in the patient-derived xenograft (PDX) model (PMID: 36374558). | 36374558 |
ARID1B Q127_Q131del IDH1 R132L | cholangiocarcinoma | no benefit | Pamiparib | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, a cholangiocarcinoma patient-derived xenograft (PDX) cell line harboring IDH1 R132L and ARID1B Q127_Q131del was insensitive to Pamiparib (BGB-290) in culture and did not inhibit tumor growth in the patient-derived xenograft (PDX) model (PMID: 36374558). | 36374558 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04164199 | Phase III | Pamiparib + Tislelizumab Pemetrexed Disodium + Tislelizumab Tislelizumab Capecitabine + Tislelizumab Pamiparib | Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies | Enrolling by invitation | USA | TUR | POL | NZL | ITA | FRA | AUS | 4 |
NCT03712930 | Phase II | Pamiparib | Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency | Terminated | USA | ESP | AUS | 1 |
NCT04614909 | Phase I | Olaparib Pamiparib Pamiparib + Temozolomide Olaparib + Pamiparib + Temozolomide | Phase 0/2 Study of Pamiparib in Newly Diagnosed and rGBM | Recruiting | USA | 0 |
NCT03150862 | Phase Ib/II | Pamiparib Pamiparib + Temozolomide | A Study Assessing BGB-290 With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma | Completed | USA | NLD | CHE | 0 |
NCT03427814 | Phase III | Pamiparib | Study of BGB-290 or Placebo in Patients With Advanced or Inoperable Gastric Cancer | Completed | USA | POL | HUN | GBR | FRA | ESP | CZE | BEL | AUS | 7 |